WO2008112307A3 - Toll-like receptor 4 deficiency and downstream effectors cause pulmonary emphysema - Google Patents

Toll-like receptor 4 deficiency and downstream effectors cause pulmonary emphysema Download PDF

Info

Publication number
WO2008112307A3
WO2008112307A3 PCT/US2008/003418 US2008003418W WO2008112307A3 WO 2008112307 A3 WO2008112307 A3 WO 2008112307A3 US 2008003418 W US2008003418 W US 2008003418W WO 2008112307 A3 WO2008112307 A3 WO 2008112307A3
Authority
WO
WIPO (PCT)
Prior art keywords
emphysema
toll
receptor
deficiency
cathepsin
Prior art date
Application number
PCT/US2008/003418
Other languages
French (fr)
Other versions
WO2008112307A2 (en
Inventor
Patty Lee
Xuchen Zhang
Original Assignee
Univ Yale
Patty Lee
Xuchen Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale, Patty Lee, Xuchen Zhang filed Critical Univ Yale
Publication of WO2008112307A2 publication Critical patent/WO2008112307A2/en
Publication of WO2008112307A3 publication Critical patent/WO2008112307A3/en
Priority to US12/558,308 priority Critical patent/US20100086546A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96466—Cysteine endopeptidases (3.4.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD

Abstract

The present invention provides compositions and methods for the detection, treatment, and prevention of emphysema/COPD. Compositions of the present invention comprise TLR4 activators, Nox3 inhibitors, and Cathepsin E inhibitors useful in the treatment or prevention of emphysema/COPD. Cathepsin E is a downstream effector of TLR4, wherein when cathepsin E is overexpressed in lung of an individual, the individual is at higher risk of developing emphysema/COPD. Cathepsin E is further identified as a biomarker useful in the identification of an individual with, or at-risk of developing emphysema/COPD.
PCT/US2008/003418 2007-03-13 2008-03-13 Toll-like receptor 4 deficiency and downstream effectors cause pulmonary emphysema WO2008112307A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/558,308 US20100086546A1 (en) 2007-03-13 2009-09-11 Toll-LIke Receptor 4 Deficiency and Downstream Effectors Cause Pulmonary Emphysema

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90690007P 2007-03-13 2007-03-13
US60/906,900 2007-03-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/558,308 Continuation-In-Part US20100086546A1 (en) 2007-03-13 2009-09-11 Toll-LIke Receptor 4 Deficiency and Downstream Effectors Cause Pulmonary Emphysema

Publications (2)

Publication Number Publication Date
WO2008112307A2 WO2008112307A2 (en) 2008-09-18
WO2008112307A3 true WO2008112307A3 (en) 2008-11-06

Family

ID=39760298

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/003418 WO2008112307A2 (en) 2007-03-13 2008-03-13 Toll-like receptor 4 deficiency and downstream effectors cause pulmonary emphysema

Country Status (1)

Country Link
WO (1) WO2008112307A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100086546A1 (en) * 2007-03-13 2010-04-08 Yale University Toll-LIke Receptor 4 Deficiency and Downstream Effectors Cause Pulmonary Emphysema
EP3624821A4 (en) * 2017-05-19 2021-01-20 The Board of Trustees of the Leland Stanford Junior University Enzastaurin and fragile histidine triad (fhit)-increasing agents for the treatment of pulmonary hypertension

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060074066A1 (en) * 2003-04-01 2006-04-06 Yale University Use of an inhibitor of cathepsin-S or -B to treat or prevent chronic obstructive pulmonary disease
US20070014719A1 (en) * 2004-09-29 2007-01-18 Reading Christopher L Steroid analogs and characterization and treatment methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060074066A1 (en) * 2003-04-01 2006-04-06 Yale University Use of an inhibitor of cathepsin-S or -B to treat or prevent chronic obstructive pulmonary disease
US20070014719A1 (en) * 2004-09-29 2007-01-18 Reading Christopher L Steroid analogs and characterization and treatment methods

Also Published As

Publication number Publication date
WO2008112307A2 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
WO2009126310A3 (en) Methods for identification and use of agents targeting cancer stem cells
WO2007092622A3 (en) Compositions and methods for treating bone
WO2008104803A3 (en) Proteins
WO2008097908A3 (en) Methods of diagnosing and prognosing lung cancer
WO2007114947A3 (en) Highly sensitive system and methods for analysis of troponin
WO2008157697A3 (en) Copolymer assay
WO2009067245A3 (en) Compositions and methods for tissue repair
WO2008014252A3 (en) Iap inhibitors
WO2008153705A3 (en) Methods of treating, diagnosing and detecting fgf21-associated disorders
WO2006017150A3 (en) Identification of markers in lung and breast cancer
WO2006031926A3 (en) Methods for the isolation and expansion of cord blood derived t regulatory cells
WO2010120942A3 (en) Histone modification patterns for clinical diagnosis and prognosis of cancer
WO2010059317A3 (en) Separation process
WO2008030986A3 (en) Molecular diagnosis and classification of malignant melanoma
WO2009156179A8 (en) Her3 as a determinant for the prognosis of melanoma
WO2008061020A3 (en) Methods of treating, diagnosing or detecting cancer
WO2007109105A3 (en) Flavivirus inhibition by sultams and related compounds
WO2008008923A3 (en) Compositions and methods for targeting cancer-specific transcription complexes
WO2010075360A3 (en) Methods for detection of sepsis
WO2009155502A3 (en) Computer-implemented methods, computer-readable media, and systems for determining one or more characteristics of a wafer
WO2007144198A3 (en) Fplr-1 inhibitors for use in diseases involving amyloid-induced inflammatory events (flipr and flipr-like) and immunecomplex-mediated diseases
WO2008122053A3 (en) Compositions, kits and related methods for the detection and/or monitoring of pseudomonas aeruginosa
MX2010004566A (en) Bordetella detection assay.
WO2008036379A3 (en) Serine hydrolase inhibitors
WO2007005672A3 (en) Treatment and prevention of respiratory diseases and conditions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08742089

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08742089

Country of ref document: EP

Kind code of ref document: A2